JPH0284401A - porous microcellulose particles - Google Patents
porous microcellulose particlesInfo
- Publication number
- JPH0284401A JPH0284401A JP63233656A JP23365688A JPH0284401A JP H0284401 A JPH0284401 A JP H0284401A JP 63233656 A JP63233656 A JP 63233656A JP 23365688 A JP23365688 A JP 23365688A JP H0284401 A JPH0284401 A JP H0284401A
- Authority
- JP
- Japan
- Prior art keywords
- cellulose
- particles
- porous
- sample
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0279—Porous; Hollow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Preparation And Processing Of Foods (AREA)
- Jellies, Jams, And Syrups (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Abstract] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は多孔性微小セルロース粒子に関するものであり
、さらに詳しくは従来のものにはない大きな比表面積と
発達した細孔構造を有し、かつ結晶形が1型であること
を特徴とする多孔性微小セルロース粒子に関するもので
ある。本発明物質は食品、医薬品の吸着担体、圧縮成形
助剤、流動性改良剤、化粧品の添加剤などに利用される
。Detailed Description of the Invention (Field of Industrial Application) The present invention relates to porous microcellulose particles, and more specifically, they have a large specific surface area and a developed pore structure that are not found in conventional particles, and The present invention relates to porous microcellulose particles characterized by having a type 1 crystal structure. The substance of the present invention is used as an adsorption carrier for foods and medicines, a compression molding aid, a fluidity improver, an additive for cosmetics, and the like.
(従来の技術)
多孔性のセルロース粒子は従来、ゲル濾過剤、セルロー
ス性イオン交換体の原料、アフィニティクロマトグラフ
ィー用担体、高分子担体、化粧品添加剤等として種々の
分野で使用されている。(Prior Art) Porous cellulose particles have been used in various fields as gel filtration agents, raw materials for cellulosic ion exchangers, carriers for affinity chromatography, polymer carriers, cosmetic additives, and the like.
その製造方法としては例えばビスコースを凝固再生浴中
に粒状で落下させてa固再生を行わせることにより16
〜170メツシユの多孔性再生セルロース粒子を得る方
法(特開昭48−60753号)や、アンモニア性水酸
化銅溶液にセルロースを溶解し、乳化剤を含むベンゼン
中に滴下してセルロース溶液を分散後、再生浴にこれを
投入してセルロース小球を得る方法(特公昭52−11
237号)、三酢酸セルロースの粒状粒子をケン化する
ことにより多孔性セルロース球状粒子を得る方法(特公
昭6312099号)などが開示されている。しかしそ
れらはクロマトグラフィー用担体として用いられるため
製品は通常湿潤した状態であり、乾燥すると収縮を起こ
して充分な細孔容積を維持することができない。As a manufacturing method, for example, viscose is dropped in granular form into a coagulation regeneration bath to perform a solid regeneration.
A method for obtaining porous regenerated cellulose particles of ~170 mesh (Japanese Patent Application Laid-Open No. 48-60753), or a method of dissolving cellulose in an ammoniacal copper hydroxide solution and dropping it into benzene containing an emulsifier to disperse the cellulose solution, A method of obtaining cellulose globules by adding it to a regeneration bath (Special Publication No. 52-11)
237) and a method for obtaining porous cellulose spherical particles by saponifying granular particles of cellulose triacetate (Japanese Patent Publication No. 6312099). However, since they are used as chromatographic carriers, the products are usually in a wet state, and when dried they shrink and cannot maintain sufficient pore volume.
またそれらはセルロースもしくはセルロース誘導体の溶
解・再生操作を行っているがために、その結晶形は■型
となっている。In addition, since these processes involve dissolving and regenerating cellulose or cellulose derivatives, their crystal form is the ■ type.
乾燥状態の多孔性セルロース粒子としては特公昭57−
45254号に、水不混和性液体中のビスコース懸濁液
を加熱することにより固化し、次いで酸分解して球状セ
ルロース粒子を得る方法が示されており、その中に「約
30%以下の気孔率を有する粒子は寸法安定性であり、
乾燥できる」との記載があるが、使用目的に適応しない
ため具体的な記述は示されていない。また、特開昭63
−90501号には、セルロースザンテートと水溶性高
分子化合物のアルカリ水溶液の混合物の微粒子状分散液
を凝固・中和後、該水溶性高分子を除去することにより
多孔性のセルロース粒子を得る方法が示されているが比
表面積に関する記載は全くない。これらとても溶解・再
生操作を行っているから製品の結晶形はやはり■型であ
る。As dry porous cellulose particles, Japanese Patent Publication No. 57-
No. 45254 describes a method for solidifying a viscose suspension in a water-immiscible liquid by heating and then acid decomposition to obtain spherical cellulose particles, in which "up to about 30% Particles with porosity are dimensionally stable;
"It can be dried", but no specific description is given because it is not suitable for the purpose of use. Also, JP-A-63
No. 90501 describes a method for obtaining porous cellulose particles by coagulating and neutralizing a fine particle dispersion of a mixture of cellulose xanthate and an alkaline aqueous solution of a water-soluble polymer compound, and then removing the water-soluble polymer. is shown, but there is no description of the specific surface area. Because these melting and regeneration operations are carried out, the crystal form of the product is still type II.
セルロースの結晶形は■型、■型、■型、■型などが知
られておりその中で特に■型は「天然セルロース」、■
型は「再生セルロース」と呼ばれている。天然セルロー
スは古来、植物繊維として食用に供しており、又、現在
では液状食品の分散安定剤や医薬品の賦形剤として広く
使用されており、再生セルロースは服飾材料であるレー
ヨン糸やキュプラ糸、前出のクロマトグラフィー用担体
としての球状粒子として使用されている。■型と■型で
は使用分野が異っており、結晶形の違いは使用目的によ
り留意すべき問題である。The crystalline forms of cellulose are known as ■-type, ■-type, ■-type, ■-type, etc. Among them, ■-type is especially known as "natural cellulose", ■
The type is called "regenerated cellulose." Natural cellulose has been used as an edible vegetable fiber since ancient times, and is now widely used as a dispersion stabilizer for liquid foods and as an excipient for pharmaceuticals.Regenerated cellulose is used in clothing materials such as rayon yarn, cupro yarn, It is used as a spherical particle as a carrier for the aforementioned chromatography. The fields of use for the type ■ and type ■ are different, and the difference in crystal form is an issue that should be kept in mind depending on the purpose of use.
比表面積の大なるセルロース粉末は有機溶媒置換法や臨
界点乾燥法を用いることにより調整し得ることが知られ
ている。(臼田誠人、紙バ技協誌、並 (4)、423
−433(1982)) Lかしそれらはおおよそ3
00Å以下の細孔を有するにとどまり、それ以上の大き
な細孔を有することはなく、またその細孔容積も充分な
ものとはいえない。It is known that cellulose powder with a large specific surface area can be prepared by using an organic solvent substitution method or a critical point drying method. (Masato Usuda, Paperback Technical Association Journal, Normal (4), 423
-433 (1982)) L or they are approximately 3
It only has pores of 00 Å or less, and does not have larger pores, and its pore volume cannot be said to be sufficient.
(本発明が解決しようとする問題点)
本発明者は従来のものとは異なる、発達した細孔構造を
互し、かつ、充分な気孔容積を有し、さらには乾燥状態
で大なる比表面積を有する多孔質の天然セルロース微小
粒子を得るために鋭意努力を重ねた結果、本発明に到達
したものである。本発明の目的は新規な多孔性の微小セ
ルロース粒子を提供することにある。(Problems to be Solved by the Present Invention) The present inventor has developed a highly developed pore structure that is different from conventional ones, has a sufficient pore volume, and has a large specific surface area in a dry state. The present invention was achieved as a result of intensive efforts to obtain porous natural cellulose microparticles having the following properties. It is an object of the present invention to provide new porous microcellulose particles.
従来知られている多孔性セルロース粒子は前述の通り、
いずれもセルロースもしくはセルロース誘導体の溶解・
再生操作を行っているがためにその結晶形は■型となっ
ており、また乾燥状態で発達した細孔構造(直径の大き
な細孔と充分な細孔容積)と大きな比表面積を合わせも
つものはなかった。As mentioned above, conventionally known porous cellulose particles are
Both are for dissolving and dissolving cellulose or cellulose derivatives.
Due to the regeneration process, its crystal form is a ■ type, and it also has a pore structure developed in the dry state (large diameter pores and sufficient pore volume) and a large specific surface area. There was no.
(問題を解決するための手段)
本発明は、結晶形が■型であり、比表面積が20rrf
/ g以上でかつ直径0.01μm以上の細孔容積が
0.3cm3/g以上の多孔構造を有し、そして平均粒
径が大きくとも100μmであることを特徴とする多孔
性セルロース微小粒子に関するものである。(Means for Solving the Problem) The present invention has a crystal form of ■ type and a specific surface area of 20rrf.
/g or more, has a porous structure with a diameter of 0.01 μm or more, a pore volume of 0.3 cm3/g or more, and an average particle size of at most 100 μm. It is.
以下、本発明について詳細に説明する。The present invention will be explained in detail below.
本発明による多孔性セルロース微小粒子の結晶形は■型
であり、ラミー、コントンリンター、木材パルプ等の天
然セルロースと同じ結晶構造を有している。さらに本発
明による多孔性セルロース微小粒子は長径と短径の比が
比較的1に近い球状を呈している場合が多く、その表面
は1μm以下の微小な孔を無数に有するような状態か、
もしくはその多孔質面と棒状のセルロース粒子が混在す
るような状態となっている。多孔性は表面のみならず内
部にも及んでおり、直径o、oiμm以上の細孔の容積
は0.3c+fl/g以上でかつ比表面積が20rd
/ g以上であるという微細細孔構造を有している。The crystalline form of the porous cellulose microparticles according to the present invention is a -type, and has the same crystal structure as natural celluloses such as ramie, konton linter, and wood pulp. Furthermore, the porous cellulose microparticles according to the present invention often have a spherical shape in which the ratio of the major axis to the minor axis is relatively close to 1, and the surface thereof may be in a state of having countless minute pores of 1 μm or less.
Alternatively, the porous surface and rod-shaped cellulose particles coexist. Porosity extends not only to the surface but also to the interior, and the volume of pores with a diameter of o, oiμm or more is 0.3c+fl/g or more and the specific surface area is 20rd.
/ g or more.
これら微細細孔構造を規定する3つの条件のいずれが欠
けても本発明の目的とする効果を発揮し得ない。一般に
細孔の直径が大きな場合、例えば0.1μm以上である
とすると細孔容積は大となりやすく、又、細孔直径が小
さな場合は比表面積が大となりやすい。しかし、特に溶
解・再生操作を取り得ない天然セルロース粒子の場合、
この3つの物性を制御することが困難であったが、本発
明による多孔性セルロース粒子はそれらを兼ね備えてお
り、そのために医薬品の吸着担体や粉体の圧縮成形助剤
として極めて優れた性質を発揮し得るものである。If any of these three conditions that define the fine pore structure are lacking, the intended effects of the present invention cannot be achieved. Generally, when the pore diameter is large, for example 0.1 μm or more, the pore volume tends to be large, and when the pore diameter is small, the specific surface area tends to be large. However, especially in the case of natural cellulose particles that cannot be dissolved or regenerated,
Although it has been difficult to control these three physical properties, the porous cellulose particles according to the present invention possess these properties, and therefore exhibit extremely excellent properties as adsorption carriers for pharmaceuticals and compression molding aids for powders. It is possible.
また本発明による多孔性セルロース粒子は平均粒径が1
00μm以下である。これは、一般に平均粒径が100
μm以上の粉体は他の粉体との混合性が悪く、粉として
の欠点を惑しるようになるためであり、例えば、医薬品
製剤の混合粉体の流動性改良剤として本発明品を用いた
場合、平均粒径が大きいと他の粉との分離が生じ、その
機能を充分に発揮し得なくなる。Furthermore, the porous cellulose particles according to the present invention have an average particle size of 1
00 μm or less. This generally means that the average particle size is 100
This is because powders larger than μm have poor miscibility with other powders, leading to problems as a powder.For example, the product of the present invention can be used as a fluidity improver for mixed powders in pharmaceutical formulations. When used, if the average particle size is large, it will separate from other powders and will not be able to fully demonstrate its function.
本発明の多孔性セルロース微小粒子は例えば以下の方法
により製造されるが、これらの方法に限定されるもので
はない。The porous cellulose microparticles of the present invention are produced, for example, by the following method, but are not limited to these methods.
本発明の多孔性セルロース微小粒子は有機溶媒に分散さ
せた微粒子状天然セルロースをスプレードライ法により
造粒、乾燥することで得ることができる。The porous cellulose microparticles of the present invention can be obtained by granulating and drying microparticulate natural cellulose dispersed in an organic solvent using a spray drying method.
セルロース微粒子の有機溶媒スラリーは種々の方法で調
整することができる。例えば、天然セルロース原料を化
学的処理(酸加水分解等)および、もしくは機械的処理
(粉砕、摩砕等)により微粒子状のセルロース粒子とし
、この時分散媒となっている水を有機溶媒で置換し、さ
らに固形分濃度を調節することでスプレードライに供す
るスラリーを調整することができる。この際、要は有機
溶媒中に微粒子状セルロースが分散している状態にして
やればよいわけだから、有機溶媒置換後のスラリーに対
し摩砕処理を加えることで目的を達成してもよい。むし
ろ有機溶媒置換操作(有機溶媒分散、濾過の繰り返し)
の作業性はその方が良好である。分散微粒子の大きさは
10μm以下好ましくは1uII+以下であることが本
発明の中間原料として適当である。天然セルロース原料
としてはセルロース■型の結晶形を有するラミー、コツ
トンリンター、木材パルプなどが用いられ、また有機溶
媒としてはアセトン、メタノール、エタノール、イソプ
ロピルアルコール、n−ヘキサン、n−ペンタン、シク
ロヘキサン、ベンゼン等の1種もしくは2種以上が使用
される。(2種以上の使用の際は、段階的な逐次置換と
なる。)スプレードライはスラリーの分散媒が有機溶媒
であるから防爆を考慮したクローズドシステムの、例え
ば窒素ガス循環型のスプレードライヤーを使用して行う
必要がある。The organic solvent slurry of cellulose particles can be prepared in various ways. For example, a natural cellulose raw material is made into fine cellulose particles by chemical treatment (acid hydrolysis, etc.) and/or mechanical treatment (pulverization, grinding, etc.), and at this time, the water serving as a dispersion medium is replaced with an organic solvent. However, by further adjusting the solid content concentration, the slurry to be subjected to spray drying can be adjusted. At this time, the point is that the particulate cellulose needs to be dispersed in the organic solvent, so the objective may be achieved by adding a grinding treatment to the slurry after replacing the organic solvent. Rather, organic solvent replacement operation (organic solvent dispersion, repeated filtration)
The workability is better that way. It is suitable for the intermediate raw material of the present invention that the size of the dispersed fine particles is 10 μm or less, preferably 1uII+ or less. As natural cellulose raw materials, ramie, cotton linters, wood pulp, etc., which have a cellulose type crystal form, are used, and as organic solvents, acetone, methanol, ethanol, isopropyl alcohol, n-hexane, n-pentane, cyclohexane, One or more types of benzene etc. are used. (If two or more types are used, they will be replaced in stages.) Spray drying uses an explosion-proof closed system spray dryer, such as a nitrogen gas circulation type spray dryer, because the slurry dispersion medium is an organic solvent. It is necessary to do so.
(発明の効果)
本発明によって得られる多孔性セルロース微小粒子は今
までに知られていない細孔構造、細孔容積及び比表面積
を有する天然セルロース粒子であり、造粒されているが
ために粉体としての自流動性に優れている。他の粉体と
混合するような場合、特に本発明品の粒度分布がシャー
プである場合、その混合粉体の流動性が極めて向上し、
例えば医薬品製剤の処方に組み入れ直接粉末圧縮法にて
錠剤を製すると錠剤の重量バラツキが著しく低減される
。また発達した細孔構造と充分な比表面積を有するがた
めに、直接粉末圧縮法における添加剤として必要な性質
である圧縮成形性に優れ、特に成形性の劣る処方系に配
合した場合においてその効果は顕著となる。さらに、ア
スピリンのような昇華性を有する生薬と本発明品を物理
混合すると主薬が細孔に吸着され、結局主薬の溶出速度
が著しく早くなることから、医薬品製剤の溶出性改善剤
として利用することも可能である。(Effects of the Invention) The porous cellulose microparticles obtained by the present invention are natural cellulose particles having a pore structure, pore volume, and specific surface area that have not been previously known. It has excellent self-flowing properties as a body. When mixed with other powders, especially when the product of the present invention has a sharp particle size distribution, the fluidity of the mixed powder is greatly improved.
For example, if it is incorporated into a pharmaceutical formulation and tablets are manufactured by direct powder compression, the weight variation of the tablets is significantly reduced. In addition, because it has a developed pore structure and a sufficient specific surface area, it has excellent compression moldability, which is a necessary property as an additive in direct powder compression, and is especially effective when added to formulations with poor moldability. becomes noticeable. Furthermore, when the present invention is physically mixed with a crude drug that has sublimation properties such as aspirin, the active ingredient is adsorbed into the pores, and the dissolution rate of the active ingredient becomes significantly faster. Therefore, it can be used as a dissolution improving agent for pharmaceutical formulations. is also possible.
本発明品は天然セルロースであるから食用として自由に
供し得ることができ、また化学的に不活性であることか
ら医薬品製剤や酵素製剤等の製剤の安定化にも寄与する
。Since the product of the present invention is made of natural cellulose, it can be freely consumed as food, and since it is chemically inert, it also contributes to the stabilization of pharmaceutical preparations, enzyme preparations, and other preparations.
また、多孔性のセルロース粒子は液体クロマトグラフィ
ー用のカラム充填剤として利用され中でも■型の結晶構
造を有するセルロース粒子はアミノ酸の光学異性体の光
学分割に使用し得ることが知られているが、本発明の多
孔性セルロース微粒子は比表面積が大であることから、
そのようなカラム充填剤として優秀な性能を有する。In addition, porous cellulose particles are used as column packing materials for liquid chromatography, and it is known that cellulose particles with a ■-type crystal structure can be used for optical resolution of optical isomers of amino acids. Since the porous cellulose fine particles of the present invention have a large specific surface area,
It has excellent performance as such a column packing material.
その他に本発明品は化粧品の配合剤としても使用し得る
。例えば固形のファンデーションに配合すると多孔性で
あること、又、粒子が大きすぎないことから、のび特性
が良くなり、またセルロスの特性上(吸湿性等)他の化
粧品配合成分や皮脂あるいは汗の含みが良好であるため
化粧(ずれしにくく、かつ軽い使用感が得られるように
なる。In addition, the product of the present invention can also be used as a compounding agent for cosmetics. For example, when blended into a solid foundation, it is porous and the particles are not too large, so it spreads well, and due to its cellulose properties (hygroscopicity, etc.), it may contain other cosmetic ingredients, sebum, or sweat. Because the makeup has good properties, makeup (does not easily come off) and has a light feeling of use.
またクリーム、乳液等の乳化型の化粧料に配合すると乳
化性が安定し、使用時ののびが軽く、使用後はさっばり
惑、かつしっとり感の優れたものとなる。In addition, when incorporated into emulsified cosmetics such as creams and emulsions, the emulsifying properties are stable, the product spreads easily during use, and has a light and moist feel after use.
実施例に先立ち、製品粒子の物性評価法及び錠剤物性の
測定方法について説明する。Prior to Examples, a method for evaluating the physical properties of product particles and a method for measuring the physical properties of tablets will be explained.
〈平均粒子系(μm)>
柳本製作所製ロータツブ式篩振盪機によりJIS標準篩
(Z8801−1987)を用いて試料50gを30分
間篩分し、累積50重量%の粒度を平均粒子径とする。<Average particle system (μm)> 50 g of sample is sieved for 30 minutes using a JIS standard sieve (Z8801-1987) using a rotary tube sieve shaker manufactured by Yanagimoto Seisakusho, and the particle size of cumulative 50% by weight is defined as the average particle diameter.
粒径が小さくて篩分は法で平均粒径が求められない場合
は顕微鏡法を用いて測定した。If the particle size was small and the average particle size could not be determined by the sieving method, it was measured using a microscope method.
顕微鏡法は試料粉末を水、エタノール、グリセリンの等
重量混合溶液に適当量分散させ、これを光学顕微鏡にて
写真撮影し、その写真に写っている個々の粒子について
粒子径を測定し、その平均をもって平均粒径とするもの
である。粒子径の測定は任意な一方向の2平行線で挟ま
れた距離として求め、検体数は200個とした。In the microscopy method, an appropriate amount of sample powder is dispersed in a mixed solution of equal weights of water, ethanol, and glycerin, and this is photographed using an optical microscope.The particle size of each particle in the photograph is measured, and the average diameter is calculated. The mean particle size is taken as the average particle size. The particle diameter was measured as the distance between two parallel lines in one arbitrary direction, and the number of samples was 200.
く細孔直径(μm)及び細孔容積(cffl/g )
>島津製作所■ポアサイザー9300を用い、水銀ポロ
シメトリーにより細孔分布を求め、細孔容積は粒子的水
銀侵入体積をもって表わした。Pore diameter (μm) and pore volume (cffl/g)
> Pore sizer 9300 manufactured by Shimadzu Corporation was used to determine the pore distribution by mercury porosimetry, and the pore volume was expressed as the volume of particulate mercury penetration.
く比表面積(ボ/g)〉 吸着物質として窒素を用い、BET法にて測定した。Specific surface area (bo/g)〉 It was measured by the BET method using nitrogen as an adsorbent.
〈結晶形〉
X線デイフラクトメーターによりX線回折を行い、その
デイフラクトプラムより判定した。<Crystal form> X-ray diffraction was performed using an X-ray diffractometer, and determination was made from the diffract plum.
く安息角(°)〉
筒井理化学器械■製安息角測定器(ターンテーブル型)
により円錐堆積法を利用して測定した。Angle of repose (°)〉 Angle of repose measuring instrument (turntable type) manufactured by Tsutsui Rikagaku Kikai ■
The measurements were made using the cone deposition method.
繰り返し数は3でその平均値をとる。The number of repetitions is 3 and the average value is taken.
く錠剤明度(kg)>
プロインド産業■製シュロインガー便度計で錠剤の径方
向に荷重を加え、破壊した時の荷重で表わす。繰り返し
数はlOでその平均値をとる。Tablet brightness (kg)> Expressed as the load when the tablet is broken by applying a load in the radial direction using a Schroinger stool tester manufactured by Pro India Sangyo ■. The number of repetitions is lO and the average value is taken.
く錠剤重量バラツキ(%)〉 錠剤10錠をそれぞれ精秤し、変動係数を求める。Tablet weight variation (%)〉 Precisely weigh each of the 10 tablets and determine the coefficient of variation.
(実施例)
実施例1
市販DPバルブを切断し、7%塩酸水溶液中で105°
Cで20分間加水分解して得られた酸不溶解残渣を中和
、洗浄、濾過・脱水したウェットケーク(水分含量50
%) 3.0kgを1042ニーダ−にて約1時間混
練、摩砕した。この摩砕ウェットケークの水分をイソブ
ロビルアルコーゼレ(以下、IPAと略)で置換し、最
終的に固形分(セルロース分)濃度が5.5重量%、水
分が0.4重量%、IPAが94.1重量%となるよう
にスラリーを調整した。このとき微粒子状セルロースは
そのほとんどが1μm以下に摩砕された状態であった。(Example) Example 1 A commercially available DP valve was cut off and heated at 105° in a 7% aqueous hydrochloric acid solution.
A wet cake (moisture content: 50
%) 3.0 kg was kneaded and ground in a 1042 kneader for about 1 hour. The water content of this ground wet cake was replaced with isobrobyl alcohol (hereinafter abbreviated as IPA), and the final solid content (cellulose content) concentration was 5.5% by weight, water content was 0.4% by weight, and IPA The slurry was adjusted so that the amount was 94.1% by weight. At this time, most of the particulate cellulose was ground to 1 μm or less.
このスラリーを窒素循環型のスプレードライヤを用い噴
霧乾燥を行ったところ、極めて球形に近い粒子から成る
粉体を得ることができた。この粉体の45μm以上の粗
粒分をカットしくJIS 2880145μ鶴による)
その篩過留分を試料Aとした。試料Aの基礎物性を第1
表に示す。When this slurry was spray-dried using a nitrogen circulation type spray dryer, a powder consisting of extremely spherical particles could be obtained. The coarse particles of 45 μm or more of this powder should be cut according to JIS 2880145μ Tsuru)
The sieved fraction was designated as sample A. The basic physical properties of sample A are
Shown in the table.
実施例2
実施例1と同様にして得られたウェットケークをIPA
に分散し、濾過・脱水、再分散を2回行い、さらに日本
精機製作所■製、ゴーリンホモジナイザー15M型を用
い、処理圧400kg/cI11で3再分散処理を行い
、これを実施例1と同様に噴霧乾燥した。乾燥前のスラ
リーは固形分濃度が9.8重量%、水分が2.5重量%
、IPAが87.7重量%という組成であった。得られ
たサンプルは標準篩(JIS Z 8801250μm
)を用いて250 p m以上の粗粒分をカットし、
その250μm以下の球状試料を試料Bとした。試料B
の基礎物性を第1表に示す。Example 2 A wet cake obtained in the same manner as in Example 1 was mixed with IPA.
The mixture was dispersed in water, filtered, dehydrated, and redispersed twice, and then redispersed three times at a processing pressure of 400 kg/cI11 using a Gorlin homogenizer 15M manufactured by Nippon Seiki Seisakusho. Spray dried. The slurry before drying has a solid content concentration of 9.8% by weight and a water content of 2.5% by weight.
The composition was 87.7% by weight of IPA. The obtained sample was passed through a standard sieve (JIS Z 8801250μm
) to cut coarse particles of 250 pm or more,
The spherical sample with a diameter of 250 μm or less was designated as sample B. Sample B
The basic physical properties of are shown in Table 1.
比較例I
実施例1と同様にして得られたウェットケーク1 kg
をアセトン21に分散し、濾過・脱水した。Comparative Example I 1 kg of wet cake obtained in the same manner as in Example 1
was dispersed in acetone 21, filtered and dehydrated.
このアセトン置換したウェットケークを五橋製作所製高
速混合造粒機NSK 250型に入れ、攪拌羽根の回転
速度500rpmで1分間解砕・造粒した。この710
u m以下の留分(JIS Z 8801710μm
による)を50°Cで18時間乾燥して球状試料Cを得
た。試料Cの基礎物性を第1表に示す。This acetone-substituted wet cake was placed in a high-speed mixing granulator model NSK 250 manufactured by Itsuhashi Seisakusho, and was crushed and granulated for 1 minute at a stirring blade rotation speed of 500 rpm. This 710
Fraction below um (JIS Z 8801710μm
) was dried at 50°C for 18 hours to obtain a spherical sample C. The basic physical properties of Sample C are shown in Table 1.
比較例2
m 販微結晶セルロース「アビセルPH−101J「旭
化成工業■製)を試料りとした。試料りの基礎物性を第
1表に示す。Comparative Example 2 A commercially available microcrystalline cellulose "Avicel PH-101J" manufactured by Asahi Kasei Industries Ltd. was used as a sample. The basic physical properties of the sample are shown in Table 1.
第 1 表
第1表を見るとわかるように、微粒状セルロスのIPA
スラリーの噴霧乾燥品である試料A及び試料Bは細孔容
積も比表面積も充分大きく、かつ、平均粒径が1100
a以下というものであった。Table 1 As can be seen from Table 1, fine granular cellulosic IPA
Sample A and Sample B, which are spray-dried slurry products, have sufficiently large pore volumes and specific surface areas, and have an average particle size of 1100.
It was below a.
ちなみに試料Bの細孔容積が試料Aのそれよりも大きい
にもかかわらず比表面積が小さいというのは細孔の大き
さが違うためである。(試料Aの細孔は試料Bのそれよ
りも小さい。)摩砕処理や噴霧乾燥を行わずに調整した
セルロース粒子である試料Cは細孔容積は充分であった
が比表面積が低く、又、既存のセルロース粉末である試
料りは細孔容積、比表面積ともに満足のいくものではな
い。Incidentally, although the pore volume of sample B is larger than that of sample A, the specific surface area is smaller because the pore sizes are different. (The pores of sample A are smaller than those of sample B.) Sample C, which is a cellulose particle prepared without milling or spray drying, had a sufficient pore volume but a low specific surface area. However, existing cellulose powder samples are unsatisfactory in both pore volume and specific surface area.
以上のように、実施例に示したような操作を行うことで
今までにその存在が知られていなかった、結晶形がI型
であり、比表面積が20rrf/g以上、直径0.01
μm以上の細孔の容積が0.3cm3/g以上でかつ平
均径粒が100μm以下であるという新規な多孔性セル
ロース微小粒子を得ることができた。As described above, by performing the operations shown in the examples, it was found that the crystal form was type I, the specific surface area was 20 rrf/g or more, and the diameter was 0.01 mm.
It was possible to obtain novel porous cellulose microparticles in which the volume of pores of μm or more is 0.3 cm 3 /g or more and the average diameter of particles is 100 μm or less.
以下、使用例により本発明の詳細な説明する。Hereinafter, the present invention will be explained in detail with reference to usage examples.
使用例1
試料A、 Bを各々90gと線用鉄工所(製)製パン
タムミル・AP−B型(使用スクリーン径0.5鵬φ)
で微粉砕した局方ツェナセチン(山本化学工業■製)6
0g、局方コーンスターチ(日数化学@製)30g、乳
tl!(DMv社製、100メツシユH20gをポリ袋
中にて3分間混合した後、局方ステアリン酸マグネシウ
ム(太平化学産業■製)を1.5g加え、更に30秒間
混合したものを、菊水製作所■製RT−S−9型ロ一タ
リー打錠機で8mmφ、121?の杵を用いて回転速度
25rp11、成形圧1000 kgf/cn!で打錠
成形し、重量 200■の錠剤を得た。その錠剤の物性
を第2表に示す。Usage example 1 90g each of samples A and B and a pantam mill manufactured by Line Ironworks, AP-B type (screen diameter used: 0.5φ)
Pharmacopoeia zenacetin (manufactured by Yamamoto Chemical Industry ■) 6
0g, Pharmacopoeia cornstarch (manufactured by Hikaku Kagaku@) 30g, milk TL! (After mixing 20 g of 100 mesh H (manufactured by DMv) in a plastic bag for 3 minutes, 1.5 g of pharmacopoeia magnesium stearate (manufactured by Taihei Kagaku Sangyo ■) was added, and the mixture was further mixed for 30 seconds. The tablets were compressed using an RT-S-9 type rotary tableting machine using a 8 mmφ, 121 cm punch at a rotation speed of 25 rp11 and a molding pressure of 1000 kgf/cn! to obtain tablets weighing 200 cm. The physical properties of are shown in Table 2.
比較使用例1
試料C,Dを使用例1と同様にして打錠成形した。結果
を第2表に示す。Comparative Example 1 Samples C and D were compressed into tablets in the same manner as Example 1. The results are shown in Table 2.
比較使用例2
市販微結晶セルロース「アビセルPtl−301J(旭
化成工業■製)を試料Eとして使用例1と同様に打錠成
形した。結果を第2表に示す。Comparative Use Example 2 A commercially available microcrystalline cellulose "Avicel Ptl-301J (manufactured by Asahi Kasei Kogyo ■)" was used as Sample E and tablet-molded in the same manner as in Use Example 1. The results are shown in Table 2.
第 2 表
第2表を見ると試料A、Bの安息角が他に比べて低いこ
とがわかる。(ここで安息角は打錠に供した混合粉体に
対する測定値である。)安息角が低いということは打錠
してできた錠剤の重量バラツキも低いであろうと予想さ
れるわけだがやはり試料A、 Bの重量バラツキも他
に比べて低い。重量バラツキという値は粉の流動性とい
うよりも打錠機の臼への充填性の良し悪しを示す値で直
接粉末圧縮法に対する粉の適応性はこの値をもって判断
されるものである。それは安息角が低くても重量バラツ
キが大きい、ということが、例えば試料りとEの間の関
係のように有りがちなことであるまた錠剤として大事な
性質の1つである硬度においても本発明品である試料A
、 Bは市販の直打用賦形剤である試料り、Eよりも高
い値をとっている。試料Cは各値ともほどほどの値をと
っているが粒径が大きくため他の粉体とのなじみが悪く
、分離・偏析が問題となる。Table 2 Looking at Table 2, it can be seen that the angles of repose of samples A and B are lower than the others. (Here, the angle of repose is a value measured for the mixed powder subjected to tableting.) If the angle of repose is low, it is expected that the weight variation of the tablets made by tableting will be low, but Sample A , B also have lower weight variations than the others. The value of weight variation indicates the quality of filling the tablet into the die of the tablet machine rather than the fluidity of the powder, and the adaptability of the powder to the direct powder compression method is determined based on this value. This is because even if the angle of repose is low, there is a large variation in weight, which is a common phenomenon, such as the relationship between sample size and E.Also, the hardness, which is one of the important properties for tablets, is also important for this invention. Sample A, which is a product
, B has a higher value than sample E, which is a commercially available excipient for direct injection. Sample C has moderate values for each value, but its large particle size makes it poorly compatible with other powders, causing problems of separation and segregation.
以上のように本発明による多孔性セルロース微小粒子は
医薬品製剤等の直接打錠用の圧縮成形助剤及び流動性改
良剤としての優秀な性質を有している。As described above, the porous cellulose microparticles of the present invention have excellent properties as a compression molding aid and fluidity improver for direct tabletting of pharmaceutical preparations.
特許出願人 旭化成工業株式会社Patent applicant: Asahi Kasei Industries, Ltd.
Claims (1)
かつ直径0.01μm以上の細孔の容積が0.3cm^
3/g以上の多孔構造を有し、そして平均粒径が大きく
とも100μmであることを特徴とする多孔性微小セル
ロース粒子The crystal form is type I, the specific surface area is 20 m^2/g or more, and the volume of pores with a diameter of 0.01 μm or more is 0.3 cm^.
Porous microcellulose particles having a porous structure of 3/g or more and an average particle size of at most 100 μm
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63233656A JP2733259B2 (en) | 1988-09-20 | 1988-09-20 | Porous microcellulose particles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63233656A JP2733259B2 (en) | 1988-09-20 | 1988-09-20 | Porous microcellulose particles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0284401A true JPH0284401A (en) | 1990-03-26 |
| JP2733259B2 JP2733259B2 (en) | 1998-03-30 |
Family
ID=16958466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63233656A Expired - Lifetime JP2733259B2 (en) | 1988-09-20 | 1988-09-20 | Porous microcellulose particles |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2733259B2 (en) |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5574150A (en) * | 1993-01-05 | 1996-11-12 | Asahi Kasei Kogyo Kabushiki Kaisha | Excipient having high compactability and process for preparing same |
| CN1051093C (en) * | 1994-09-16 | 2000-04-05 | 中国科学院广州化学研究所 | Method for preparing nano-scale microcrystalline cellulose powder by solvent method |
| JP2004204380A (en) * | 2002-12-25 | 2004-07-22 | Asahi Kasei Corp | Cellulose-based material with large specific surface area |
| WO2005011836A1 (en) * | 2003-07-29 | 2005-02-10 | University Of York | A separation process |
| US6946117B1 (en) | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
| JP2005255618A (en) * | 2004-03-11 | 2005-09-22 | Asahi Kasei Chemicals Corp | A solid pharmaceutical composition containing a poorly water-soluble active ingredient and porous cellulose particles. |
| JP2005255619A (en) * | 2004-03-11 | 2005-09-22 | Asahi Kasei Chemicals Corp | Solid formulation composition containing sublimable active ingredient and porous cellulose particles |
| WO2006115198A1 (en) | 2005-04-22 | 2006-11-02 | Asahi Kasei Chemicals Corporation | Porous cellulose aggregate and molding composition thereof |
| JP2007103540A (en) * | 2005-09-30 | 2007-04-19 | Nippon Chemicon Corp | Separator for capacitor and capacitor using same |
| US7790145B2 (en) | 1997-09-29 | 2010-09-07 | Novartis Ag | Respiratory dispersion for metered dose inhalers |
| US7939101B2 (en) | 2000-07-05 | 2011-05-10 | Asahi Kasei Kabushiki Kaisha | Cellulose powder |
| US8597686B2 (en) | 2004-01-30 | 2013-12-03 | Asahi Kasei Chemicals Corporation | Porous cellulose aggregate and formed product composition comprising the same |
| US8877162B2 (en) | 2000-05-10 | 2014-11-04 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery |
| US9421166B2 (en) | 2001-12-19 | 2016-08-23 | Novartis Ag | Pulmonary delivery of aminoglycoside |
| JP2020026480A (en) * | 2018-08-10 | 2020-02-20 | 日揮触媒化成株式会社 | Porous cellulose particle, method of manufacturing the same, and cosmetic for cleaning |
| JP2020050840A (en) * | 2018-09-28 | 2020-04-02 | 日揮触媒化成株式会社 | Porous cellulose particles, method for producing the same, and cosmetics |
| WO2020260385A1 (en) * | 2019-06-25 | 2020-12-30 | Aston University | Mesoporous polymeric particulate material |
| WO2021033742A1 (en) | 2019-08-20 | 2021-02-25 | 日揮触媒化成株式会社 | Particles containing starch, method for producing same, and cosmetic preparation |
| WO2022176940A1 (en) | 2021-02-19 | 2022-08-25 | 日揮触媒化成株式会社 | Coated particle, method for producing same, and cosmetic |
| US11806421B2 (en) | 2018-06-29 | 2023-11-07 | Jgc Catalysts And Chemicals Ltd. | Porous-cellulose particles and production method thereof, and cosmetic |
| WO2024106527A1 (en) | 2022-11-17 | 2024-05-23 | 花王株式会社 | Porous cellulose particles |
-
1988
- 1988-09-20 JP JP63233656A patent/JP2733259B2/en not_active Expired - Lifetime
Cited By (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5574150A (en) * | 1993-01-05 | 1996-11-12 | Asahi Kasei Kogyo Kabushiki Kaisha | Excipient having high compactability and process for preparing same |
| CN1051093C (en) * | 1994-09-16 | 2000-04-05 | 中国科学院广州化学研究所 | Method for preparing nano-scale microcrystalline cellulose powder by solvent method |
| US6946117B1 (en) | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
| US9554993B2 (en) | 1997-09-29 | 2017-01-31 | Novartis Ag | Pulmonary delivery particles comprising an active agent |
| US7790145B2 (en) | 1997-09-29 | 2010-09-07 | Novartis Ag | Respiratory dispersion for metered dose inhalers |
| US8877162B2 (en) | 2000-05-10 | 2014-11-04 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery |
| US7939101B2 (en) | 2000-07-05 | 2011-05-10 | Asahi Kasei Kabushiki Kaisha | Cellulose powder |
| US8221789B2 (en) | 2000-07-05 | 2012-07-17 | Asahi Kasei Chemicals Corporation | Cellulose powder |
| US9421166B2 (en) | 2001-12-19 | 2016-08-23 | Novartis Ag | Pulmonary delivery of aminoglycoside |
| JP2004204380A (en) * | 2002-12-25 | 2004-07-22 | Asahi Kasei Corp | Cellulose-based material with large specific surface area |
| WO2005011836A1 (en) * | 2003-07-29 | 2005-02-10 | University Of York | A separation process |
| US8597686B2 (en) | 2004-01-30 | 2013-12-03 | Asahi Kasei Chemicals Corporation | Porous cellulose aggregate and formed product composition comprising the same |
| JP2005255619A (en) * | 2004-03-11 | 2005-09-22 | Asahi Kasei Chemicals Corp | Solid formulation composition containing sublimable active ingredient and porous cellulose particles |
| JP2005255618A (en) * | 2004-03-11 | 2005-09-22 | Asahi Kasei Chemicals Corp | A solid pharmaceutical composition containing a poorly water-soluble active ingredient and porous cellulose particles. |
| WO2006115198A1 (en) | 2005-04-22 | 2006-11-02 | Asahi Kasei Chemicals Corporation | Porous cellulose aggregate and molding composition thereof |
| JP5240822B2 (en) * | 2005-04-22 | 2013-07-17 | 旭化成ケミカルズ株式会社 | Porous cellulose aggregate and molded body composition thereof |
| US8153157B2 (en) | 2005-04-22 | 2012-04-10 | Asahi Kasei Chemicals Corporation | Porous cellulose aggregate and molding composition thereof |
| US8771742B2 (en) | 2005-04-22 | 2014-07-08 | Asahi Kasei Chemicals Corporation | Porous cellulose aggregate and molding composition thereof |
| JP2007103540A (en) * | 2005-09-30 | 2007-04-19 | Nippon Chemicon Corp | Separator for capacitor and capacitor using same |
| US11806421B2 (en) | 2018-06-29 | 2023-11-07 | Jgc Catalysts And Chemicals Ltd. | Porous-cellulose particles and production method thereof, and cosmetic |
| JP2020026480A (en) * | 2018-08-10 | 2020-02-20 | 日揮触媒化成株式会社 | Porous cellulose particle, method of manufacturing the same, and cosmetic for cleaning |
| JP2020050840A (en) * | 2018-09-28 | 2020-04-02 | 日揮触媒化成株式会社 | Porous cellulose particles, method for producing the same, and cosmetics |
| WO2020260385A1 (en) * | 2019-06-25 | 2020-12-30 | Aston University | Mesoporous polymeric particulate material |
| CN114222560A (en) * | 2019-06-25 | 2022-03-22 | 阿斯顿大学 | Mesoporous polymeric particulate material |
| US20220354791A1 (en) * | 2019-06-25 | 2022-11-10 | Aston University | Mesoporous polymeric particulate material |
| WO2021033742A1 (en) | 2019-08-20 | 2021-02-25 | 日揮触媒化成株式会社 | Particles containing starch, method for producing same, and cosmetic preparation |
| WO2022176940A1 (en) | 2021-02-19 | 2022-08-25 | 日揮触媒化成株式会社 | Coated particle, method for producing same, and cosmetic |
| WO2024106527A1 (en) | 2022-11-17 | 2024-05-23 | 花王株式会社 | Porous cellulose particles |
| KR20250111094A (en) | 2022-11-17 | 2025-07-22 | 카오카부시키가이샤 | Porous cellulose particles |
| EP4620997A1 (en) | 2022-11-17 | 2025-09-24 | Kao Corporation | Porous cellulose particles |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2733259B2 (en) | 1998-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0284401A (en) | porous microcellulose particles | |
| US4744987A (en) | Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation | |
| Chatlapalli et al. | Physical characterization of HPMC and HEC and investigation of their use as pelletization aids | |
| JP2642486B2 (en) | Ultrafine particle method for poorly soluble drugs | |
| TWI438011B (en) | Oral composition for oral administration and preparation method thereof | |
| AU2015265924B2 (en) | Method for the production of granules comprising surface-reacted calcium carbonate | |
| EP0193984B1 (en) | Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation | |
| IL104087A (en) | Spheronization compositions containing microcrystalline cellulose and hydrocolloid process for their preparation and solid dosage form thereof | |
| KR20010032777A (en) | Cellulose dispersion | |
| JPS6011414A (en) | Granular n-acetyl-p-aminophenol composition and manufacture | |
| Garcia-Fernandez et al. | New multifunctional pharmaceutical excipient in tablet formulation based on citric acid-cyclodextrin polymer | |
| JPH0420938B2 (en) | ||
| HU217798B (en) | Process for the preparation of particulate S (+) ibuprofen and compositions containing it | |
| JP2535054B2 (en) | Porous cellulose particles | |
| CA2702055C (en) | Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof | |
| JP4306965B2 (en) | Bulking and decomposing composition, method for achieving it and use thereof | |
| JP2859919B2 (en) | Method for improving dissolution of poorly soluble drugs | |
| HUP0101222A2 (en) | Mannite in powder form and process for producing thereof | |
| Krueger et al. | “MCC SANAQ® burst”—a new type of cellulose and its suitability to prepare fast disintegrating pellets | |
| JP2918824B2 (en) | Dechlorination agent and method for producing the same | |
| Sarkar et al. | Microcrystalline cellulose: An overview | |
| JPH09301851A (en) | Crystalline medicine particle excellent in compression molding property and production of the same compound | |
| JP7219617B2 (en) | Method for producing pharmaceutical composition containing fine particles of poorly soluble drug | |
| CN1048396C (en) | Granular preparation | |
| SARKAR | STUDIES ON PELLET COMPOSITION AND FORMATION IN EXTRUSION-SPHERONIZATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081226 Year of fee payment: 11 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081226 Year of fee payment: 11 |